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htcense.Abstract Purpose: The aim of this study was to investigate the potential impact of PET/CT on the
initial staging of lymphoma with comparison to each of the PET and CT components alone.
Materials and methods: PET/CTs from 37 patients with lymphoma undergoing initial staging were
studied. Review of PET, CT and PET/CT images were done and staging of each patient by each
modality was assigned and compared together. Clinical follow-up, additional imaging and histology
served as the standard of reference.
Results: PET/CT correctly diagnosed 83 nodal regions as positive for lymphomatous involvement
versus 61 and 57 detected by PET and CT respectively. The respective sensitivities, speciﬁcities, and
accuracies for the detection of nodal involvement were: PET: 88.4%, 65%, 94%, CT 89.1%, 60.1%,
96.1%, PET/CT 96.3%, 88.3%, 98.2%. PET/CT also correctly identiﬁed more extra-nodal lesions
(n= 24) than CT (n= 16) and PET (n= 15). Correct staging was more accurate at PET/CT
(n= 31) in comparison to PET alone (n= 23) and CT alone (n= 21).
Conclusions: PET/CT was superior to PET and CT in the initial staging of lymphoma with signif-
icant better performance compared to PET and CT to clarify nodal and extra-nodal involved sites.
The application of PET/CT rather than CT or PET is likely to be more beneﬁcial.
 2013 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
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Malignant lymphomas are considered one of the most curable
forms of cancer (1). Limitation of long term side effects of
treatment is now of great concern as the improvement of treat-
ment enhanced higher survival rate with long life expectancy
(2,3). The choice of treatment strategy and prognosis of lym-
phoma essentially depends on grade, histological subtype
and stage of the disease (1). Several classiﬁcations exist for
lymphoma, including the Ann Arbor classiﬁcation withProduction and hosting by Elsevier B.V.
2.12.008
332 A.I. Kamel et al.Cotswolds modiﬁcations and the Revised European–American
Lymphoma (REAL) classiﬁcation (4,5).
Staging with traditional imaging methods has been based
on the morphological imaging techniques such as computed
tomography (CT), MRI, and ultrasonography (US), however
these techniques have signiﬁcant limitations. For example,
CT is based on lymph node size so it neither identiﬁes malig-
nant involvement in normal-size lymph nodes nor differenti-
ates between malignant and inﬂammatory enlargement of
lymph nodes. MRI is the modality of choice in assessing bone
marrow and central nervous system inﬁltration, but it is not
convenient for the entire bone marrow routine imaging. This
problem becomes more evident in assessment of the response
to treatment, in which anatomical imaging procedures are un-
able to differentiate residual or recurrent tumor from ﬁbrotic
or necrotic tissues (6–11). Therefore, functional imaging with
[18F] ﬂuorodeoxyglucose (FDG) positron emission tomogra-
phy (PET) has been proposed to play a major role in the stag-
ing, restaging and therapy monitoring of malignant lymphoma
(12,13).
18F-ﬂuorodeoxyglucose (18F-FDG) is a glucose analog
that provides unique information about glucose metabolism
of normal and abnormal tissues; it is preferentially taken up
and accumulated in the malignant cells relative to nonmalig-
nant cells (14). However, the PET is limited by the lack of mor-
phological information and low anatomical resolution (12),
thus fusion of images of PET and CT obtained at the same po-
sition provides the precise anatomical and functional informa-
tion about the lesions with increased glucose metabolism over
the whole body in a single session (15).
The aim of this study was to investigate the potential im-
pact of PET/CT on the initial staging of lymphoma with com-
parison to each of the PET and CT components alone.
2. Materials and methods
2.1. Patients
This study included 37 patients 23 men and 14 women with a
mean age of 52 ± 14 years (range 21–65 years) who were re-
ferred to undergo FDG PET/CT for initial staging (22 Non-
Hodgkin lymphoma and 15 Hodgkin disease). In all patients,
the diagnosis of lymphoma had been conﬁrmed previously
by means of biopsy. Our institutional review board approved
the study protocol and informed consent was obtained from
all patients. All patients fasted for at least 6 h to lower insulin
and blood sugar levels. All PET/CT studies were performed in
normoglycemia (<120 mg/dl), PET/CT was done 60 min after
I.V. administration of approximately 7 MBq/kg body weight
of FDG (upto 550 MBq).2.2. The PET/CT technique
Combined PET/CT scans were performed on (Biograph, Sie-
mens) system, consisting of a dedicated PET scanner and a
64-slice CT scanner. Scans were acquired from skull base to
mid-thigh level. The CT scan component was obtained before
the PET component using the following parameters: 130 kV,
100 mA, 1-s tube rotation, 4-mm slice collimation, and bed
speed of 8 mm/s. Patients were positioned supine with arms
up whenever tolerated to avoid artifact, they were allowed tomaintain shallow respiration during scanning. The I.V. non-io-
nic contrast medium (2 ml/kg, 5 ml/s) was administered
immediately before CT. Subsequently, PET data were acquired
in 5–7 bed positions (depending on patient height) for 3 min
per bed position. CT images were used for attenuation correc-
tion of the 18F-FDG PET emission data.18FDG-PET, CT
and fused 18FDG-PET/CT images were reviewed on the ded-
icated workstation.
2.3. Image interpretation
A lesion was considered PET-positive if there was focal FDG
uptake increase higher than the background activity of soft tis-
sues that was not explained by physiological activity. CT was
used to classify lesions based on lymph node size criteria
(diameter >10 mm) or extra-nodal abnormality.
On PET/CT, a lymph node was considered abnormal if
there was any or both of FDG uptake increase or abnormal
size. Regarding extra nodal lesions, they were classiﬁed as
abnormal if there is focal FDG uptake increase and/or CT
pathological morphological features (regardless of the FDG
uptake). The Ann Arbor classiﬁcation (16) was applied in all
patients. Disease extent was classiﬁed according to this system
for each modality (CT, PET and PET/CT). Quantitative eval-
uation of each focal radiotracer uptake was done using the
standard maximum uptake value. SUVmax, and a cut-off va-
lue of 2.0 was used to deﬁne a lesion as pathological.
2.4. Standard of reference
All patients had lymph node biopsy for histological diagnosis
of disease but systematic biopsy of all sites for staging was not
performed. All patients were subjected to clinical evaluation
and follow-up for at least 4 months (range 4–18 months).
Biopsy (n= 21 patients), and follow up (clinically and by
radiological imaging) served as the reference standard. True
sites of disease were assigned to sites with concordant positive
ﬁndings of clinical evaluation, CT, PET, and PET/CT. Con-
versely, true absence of disease was assigned in concordant
negative ﬁndings of clinical evaluation, CT, PET, and PET/
CT. If there is discordance between PET, CT, and PET/CT,
follow up and response to therapy were used. Lesions were re-
garded as true positive if abnormalities either persisted on a
follow-up PET or CT scan with no interval treatment or re-
solved on a follow-up scan in patients that had received inter-
val treatment. Lesions that resolved on follow-up scanning
without interval treatment were regarded as false positive.2.5. Staging and analysis of nodal regions
We analyzed 13 lymph node regions per patient originally de-
ﬁned by Kaplan and Rosenberg [17]. Therefore, we analyzed
481 lymph node regions. Ann Arbor classiﬁcation was used
for staging [16] from the number of positive nodal and extra-
nodal regions by each of PET, CT, and PET/CT.2.6. Statistical analysis
Accuracy, sensitivity, speciﬁcity of PET, CT and PET/CT were
calculated and compared using the unpaired t test and the
Table 1 Summary of statistical analysis of lymph node
detection.
PET CT PET/CT
True positive 61 57 83
False negative 33 37 11
False positive 23 15 7
Accuracy (%) 88.4 89.1 96.3
Sensitivity (%) 65 60,1 88.3
Speciﬁcity (%) 94 96.1 98.2
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correlation. A p value <0.05 was considered signiﬁcant.
3. Results
Thirty-seven patients with lymphoma were included in this
study, according to the reference standard: ninety-four nodal
regions and 29 extra nodal lesions were involved by lympho-
matous inﬁltration.3.1. Analysis of positive nodal regions
The number of true positive lymph node groups determined by
PET, CT and PET/CT were respectively 61, 57, and 83 (Table
1). The false negative lymph node groups at PET were 33, at
CT were 37, and at PET/CT were 11. On the other hand false
positive lymph node groups at PET, CT and PET/CT were
respectively 23, 15, and 7. The sensitivities, speciﬁcities, and
accuracies for the detection of nodal involvement were respec-
tively: PET: 88.4%, 65%, 94%, CT 89.1%, 60.1%, 96.1%,
PET/CT 96.3%, 88.3%, and 98.2%.
PET/CT performed signiﬁcantly better than PET
(p< 0.001) for sensitivity, speciﬁcity, and accuracy. In addi-
tion, PET/CT performed signiﬁcantly better than CT as re-Fig. 1 Coronal PET/CT of different patients with lymphoma: (A) S
LNs) (C) Stage IV: LT iliac LN and bilateral iliac bone inﬁltration.gards accuracy and sensitivity (p< 0.001) as well as for
speciﬁcity (P= 0.043). (Figs. 1–4).
3.2. Analysis of extra-nodal lesions
Of 29 extra-nodal lesions diagnosed by the gold standard,
PET/CT detected 24 extra-nodal lesions, PET 15, and CT 16
sites (Tables 2 and 3). PET/CT performed signiﬁcantly better
in detecting extra-nodal lesions than PET (p= 0.016) and
CT (p= 0.03). The distribution of extra-nodal lesions was as
follows bone 11, lung 7, abdominal 8 (liver 3, spleen 3, colon
1, and adrenal 1), head and neck 2 (orbit 1, nasopharynx 1)
and skin 1. Of the involved 11 bone sites, PET correctly noted
seven; PET/CT 8, while three were detected at CT. Of seven
lung sites, PET correctly detected three, while CT and PET/
CT detected all. For remaining 14 lesions, PET correctly iden-
tiﬁed 8, CT 9 and PET/CT 12. False negative extra-nodal sites
at PET, CT and PET/CT were 14, 13, and 5 respectively while
false positive extra-nodal sites were 5, 5, and 3 for PET, CT
and PET/CT respectively (Figs. 5–7).
3.3. Analysis of assigned staging (compared to reference
standard)
PET alone determined the correct stage of 23 patients (62.2%),
and incorrectly assigned a higher stage in four patients (10.8%)
and a lower stage in 10 patients (27%) (Table 4). CT alone de-
termined the correct stage of 21 patients (56.8%). CT incor-
rectly assigned a higher stage to two patients (5.4%) and a
lower stage in 14 patients (37.8%). Finally, PET/CT deter-
mined the correct stage of 31 patients (83.8%) PET/CT incor-
rectly assigned a higher stage to two patients (5.4%) and a
lower stage in four patients (10.8%).
PET/CT correctly resulted in a higher stage than CT in 10
(27%) patients while PET/CT did not downstage any of CT re-
sults. On the other hand, PET/CT correctly upstaged PET intage I (subcarinal LNs) (B) Stage II (mediastinal and LT cervical
Fig. 2 Stage IIIS: lymphomatous inﬁltration of RT cervical LNs and spleen (A, B) CT, (C, D) PET and (E, F) PET/CT.
Fig. 3 Stage IIIE Coronal PET/CT showing the inﬁltration of
mediastinal LNs (A) and liver (B).
Fig. 4 Stage III lymphoma with the inﬁltration of supra- and
infra-diaphragmatic LNs. (A, B) Coronal PET/CT.
Table 2 Correct detection of extra-nodal sites by PET, CT
and PET/CT.
Standard reference PET CT PET/CT
Bone 11 7 3 8
Lung 7 3 7 7
Abdominal 8 3 4 6
Head and neck 2 1 1 2
Skin 1 1 1 1
Total 29 15 16 24
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(5.4%) (Table 5). PET/CT incorrectly upstaged two cases,
which were correctly staged by PET alone. There was signiﬁ-
cant better performance of PET/CT in the staging of lympho-
ma patients in comparison to CT alone (p= 0.004), while
PET/CT showed a trend toward better staging performance
than PET (p= 0.061).
4. Discussion
Adequate staging of lymphoma before initiating therapy is
mandatory, taking into account the balance between efﬁcacy
and risks of toxicity and long-term adverse effects (18). Owing
to the fact that lymphoma can involve almost any part of the
body, its staging requires a wide range of diagnostic modali-ties, including structural and functional imaging in addition
to invasive procedures like bone marrow biopsy. The value
of FDG-PET in staging and restaging of lymphoma has al-
ready been shown by many reports (19–21). However, because
Table 3 Statistical analysis of extra-nodal site detection.
Extra-nodal
PET CT PET/CT
True positive 15 16 24
False negative 14 13 5
False positive 5 5 3
Accuracy (%) 52 55 82.8
Fig. 5 False FDG-PET uptake of LT lung subsegmental
consolidation with absent FDG uptake of anterior mediastinal
lymphomatous mass (A) PET, (B) PET/CT.
Fig. 7 BM lymphomatous inﬁltration in two different patients
(A,B): sternum and (C, D): LT iliac bone, showing FDG avid
uptake noted at PET/CT (B, D) with no corresponding CT
abnormalities (A, C).
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(22). In addition, FDG is not absolutely tumor-speciﬁc and
can be increased with increased glucose utilization leading to
FDG accumulation and false positive ﬁndings (23). Therefore,
the additional value of fused imaging with PET/CT can help to
localize areas of FDG accumulation with complementary CT
anatomic information (14).
Several reports showed the higher sensitivity and speciﬁcity
of PET/CT in the assessment of lymphoma when compared
with CT and PET alone or when compared to conventional
diagnostic methods (i.e., contrast-enhanced CT and bone mar-
row biopsy) (11,12,16,24,25).
This better performance of PET/CT in comparison to PET
and CT alone can be attributed to the ability of PET
component to rule out disease in CT-normal appearing lymph
nodes or extra-nodal sites while CT can pick lesions which can
be missed by PET because of either size or absence of FDG up-
take (26).
The ability of PET/CT to detect more lymph node groups
than PET or CT alone was conﬁrmed in many literatures
(27,28). Girinsky and colleagues (29) also speciﬁcally studiedFig. 6 Small right lung lymphomatous nodule with no signiﬁcant FD
(C) axial PET/CT.patients with early-stage HD, pretreatment CT and FDG-
PET scans were performed and showed that FDG-PET helped
to delineate lymph nodes that were otherwise undetectable on
a CT scan in 36% of patients. In another study (27), PET/CT
correctly diagnosed 92 of 117 nodal regions with lymphoma-
tous inﬁltration versus 68 for PET and 64 for CT. The respec-
tive sensitivities, speciﬁcities, and accuracies were: 99%, 100%,
and 99.8% for PET/CT, 68%, 97.5%, and 92.2% for PET,
and 70%, 100%, and 94.7% for CT. PET/CT performed sig-
niﬁcantly better than PET (p< 0.001 for sensitivity, speciﬁc-
ity, and accuracy) and CT (p< 0.001 for sensitivity and
accuracy).
Results of our study are coherent with these studies, as for
the group of patients studied; PET/CT was able to add impor-
tant information not available from CT or PET alone. PET/
CT was superior to PET and CT in correctly detecting the
more involved lymph node group as well as performing signif-
icantly higher than PET and CT in the classiﬁcation of lymph
node groups as positive or negative for lymphomatous inﬁltra-
tion. Our result conﬁrmed the higher accuracy of PET/CT in
the detection of nodal involvement. The sensitivities, speciﬁci-
ties, and accuracies for the detection of nodal involvementG uptake (A) CT mediastinal window, (B) CT lung window and
Table 4 Final staging of patients.
Stage Standard reference PET CT PET/CT
Correct Incorrect Correct Incorrect Correct Incorrect
Up Down Up Down Up Down
I 9 7 2 0 6 1 2 8 1 0
II 12 7 1 4 6 1 5 10 1 1
III 9 5 1 3 5 0 4 7 0 2
IV 7 4 0 3 4 0 3 6 0 1
Total 37 23 4 10 21 2 14 31 2 4
N.B.: Up = incorrect upstaging and down = incorrect down staging.
Table 5 Correction of PET and CT staging by PET/CT.
PET CT
Correct PET/CT up-staging 8 10
Correct PET/CT down staging 2 0
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96.1%, PET/CT 96.3%, 88.3%, 98.2%. PET/CT performed
signiﬁcantly better than PET (p< 0.001 for sensitivity, speci-
ﬁcity, and accuracy). Also PET/CT performed signiﬁcantly
better than CT as regards accuracy and sensitivity
(p< 0.001) as well as for sensitivity (P= 0.043).
Several reports showed that PET/CT can detect more
extra-nodal disease sites than PET or CT (27). In the study car-
ried out by Fueger and colleagues (27), they concluded that
PET/CT was signiﬁcantly better in detecting extra-nodal
lesions than CT (p< 0.016) and PET (p= 0.06). Of the 36
extra-nodal lesions by the gold standard, PET/CT detected
25 extra-nodal lesions versus 16 by CT and 9 by PET.
We obtained similar results and supported this theory, as of
29 extra-nodal sites shown by standard reference, PET/CT was
able to correctly determine 24 while PET and CT correctly de-
tected only 15 and 16 respectively. The performance of PET/
CT was signiﬁcantly better in detecting extra-nodal lesions
than PET (p= 0.016) and CT (p= 0.03).
Detection of bone marrow (BM) lymphomatous inﬁltration
is important in the management of lymphoma as BM disease is
present at the time of diagnosis in approximately 50%–80% of
patients with low-grade NHL, 25%–40% of those with high-
grade NHL, and 5%–14% of those with Hodgkin’s disease
(30,31). In the opinion of Pelosi and colleagues (32) PET/CT
cannot replace BM biopsy in the evaluation of bone marrow
disease as they had four PET/CT false negative cases in their
series (in all of them, BMB reported a bone marrow involve-
ment <20%). However, Ribrag and colleagues (33) suggested
that noninvasive morphologic imaging (e.g.MR imaging) and
metabolic imaging (e.g. PET/CT) could be superior to bone
marrow biopsy for bone marrow assessment in aggressive lym-
phomas. Moulin-Romsee and colleagues (34) recommended
that whenever possible, F-FDG PET/CT should be used at
the initial staging of HL patients as it may uncover unsus-
pected bone/bone marrow lesions and so can improve diagno-
sis and staging and may be used to direct biopsy to foci outside
the routine iliac bone marrow sampling sites (35).
In our series, we had 11 bone inﬁltration sites which were
determined by the gold standard, of which PET/CT pickedup 8 (72.7%), PET detected 7 (63.6%) while CT detected only
three (27.3%).
A growing body of the literature reports a higher level of
correct staging of PET/CT in comparison to PET or CT alone
(12,27,36). This correction may be up or down-staging respec-
tively (22.6% /9.6% in a series of 31 patients (37), 7.5% / 9.5%
in a series of 53 patients (38), and 31% /1% in a series of 103
patients (39). In a recent systematic review, the overall sensitiv-
ity and speciﬁcity of FDG PET/CT for the initial staging of
NHL and Hodgkin’s disease were 97% and 100%, respectively
(40). Fouge`re and colleagues (12) in the initial staging of 12 pa-
tients with lymphoma achieved correct staging by PET/CT in
this entire patient group. While, another study (4) showed that
PET/CT was more accurate than conventional imaging modal-
ities in the assessment of pediatric lymphoma as PET/CT mod-
iﬁed the initial staging and treatment planning in 26.8% of
patients, upstages 12.2% patients and down stages 14.6% of
patients. In the study of Fueger and colleagues (27) for 45 pa-
tients with indolent lymphoma, the correct stage was deter-
mined by PET/CT in 76%, by PET alone in 62% and by CT
alone in 58%, PET/CT correctly assigned a higher stage than
CT in 18% and in a higher stage than PET in 20%. PET/CT
correctly down staged 4% of patients compared to PET. While
PET/CT did not downstage any CT result. Pelosi colleagues
(32) showed that whole-body FDG-PET/CT allowed correct
staging of 29/30 (96.7%) of HL, and 32/35 (91.4%) of NHL
when compared to the standard technique, PET/CT correct
upstaging in three cases (10%) of HL and four cases (11.4%)
of NHL.
Our results further conﬁrm this view; correct staging was
higher by PET/CT in comparison to PET and CT alone.
Determination of the correct stage was achieved by PET/CT
in 31 patients (83.8%), while PET alone in 23 patients
(62.2%) and CT alone in 21 patients (56.8%).
Four patients were incorrectly assigned a higher stage at
PET alone while this number was reduced to two at CT alone
and at PET/CT. On the other hand incorrect down-staging by
PET/CT, PET, and CT was respectively 4, 10, and 14 patients.
PET/CT impacts not only the staging, but also the therapy
protocol, in lymphoma staging, PET/CT tends to upstage
rather than downstage tumors (41). Hutchings and colleagues
(42) studied 30 patients with early-stage HD, and showed that
when staging using FDG-PET/CT compared to CT would
have resulted in an increase in the treated volume in seven pa-
tients and a decrease in the treated volume would have oc-
curred in two patients. In addition, Pommier and colleagues
(43) reported that with integration of PET, there was a change
Potential impact of PET/CT on the initial staging of lymphoma 337in radiation plan initially created with CT information alone in
12.9% of 137 patients with early-stage HD.
For our series, PET/CT correctly resulted in upstaging CT
results in 10 (27%) patients while PET/CT did not downstage
any of CT results attributed to the selected image interpreta-
tion criteria which make the down-staging of CT by PET/CT
not possible. On the other hand, PET/CT correctly upstaged
PET in eight patients (21.6%) and down-staged it in two pa-
tients (5.4%). PET/CT incorrectly upstaged two cases that
were correctly stages by PET alone. In comparison to PET
and CT alone, PET/CT correctly staged more patients, PET/
CT showed statistically better performance than CT alone in
correct staging (p= 0.004), while PET/CT showed a trend to-
ward better performance than PET alone (p= 0.061).
We had some limitations in our study, ﬁrst is the inability to
biopsy every suspicious lesion as it would not be ethical, this
resulted in a relatively low number of patients with a reliable
reference standard. In this study, we used a number of regions
instead of patients in statistical analysis to avoid the effect of
coexistence of true and false results in the same patient on
our analysis. False positive FDG accumulation in various be-
nign conditions and false negative FDG-uptake were other
problems that may represent potential pitfalls and limitations
of PET/CT because such accumulation is not tumor speciﬁc.
5. Conclusion
In the current study, PET/CT was signiﬁcantly superior to
PET and CT in the detection of lymphomatous inﬁltration
of lymph node groups and to clarify more extra-nodal involved
sites. PET/CT correctly staged more patients than CT or PET
with a higher diagnostic accuracy than PET and CT alone that
can provide valuable additional information for the initial
staging of patients with lymphoma. Thus, the application of
PET/CT rather than CT or PET is likely to be more beneﬁcial.
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